Spinal muscular atrophy (SMA), a genetic neurodegenerative disorder, is caused by mutations or deletions in the survival of motor neuron 1 (SMN1) gene that result in SMN deficiency. SMN deficiency impairs microtubule networks in Smn-deficient cells and in SMA-like motor neuron cultures. Microtubule defects can be restored by knockdown of the stathmin gene (Stmn), which is upregulated in SMA. However, whether in vivo reduction of stathmin levels could improve the pathology of SMA has not been investigated. Here we generated SMA-like mice in a Stmn knockout (KO) background through a series of genetic crosses. Analyses of motor performance and histology showed that heterozygous StmnKO (Stmn ) ameliorates some SMA defects, with increased microtubule densities in sciatic axons, improved motor performance, enhanced NMJ maturation, and mitigated neuroinflammation. However, Stmn deletion does not prolong the lifespan of SMA-like mice, suggesting that stathmin dysregulation and microtubule disruption are not a cause but rather a consequence of SMA pathology. This work demonstrates that limiting the amount of stathmin in SMA-like mice is effective in reducing their neuromuscular defects, whereas induced aberrant expression of stathmin in SMA-like animals is detrimental.
Introduction
Spinal muscular atrophy (SMA) is an incurable neurodegenerative disorder characterized by α-motor neuron death, which leads to progressive muscle weakness and paralysis (Pearn, 1980) . SMA is caused by homozygous deletion or loss-of-function mutations in the human survival of motor neuron gene 1 (SMN1) (Brzustowicz et al., 1990; Bussaglia et al., 1995; Clermont et al., 1995; Lefebvre et al., 1995) . The paralogue gene, SMN2, cannot compensate for the loss of SMN1 due to a C-to-T transition in exon 7. The resulting SMN transcript lacks exon 7 and thus produces an unstable, C-terminal truncated SMN protein (Lorson et al., 1999; Monani et al., 1999) . The copy number of SMN2 determines the residual SMN level, which correlates with the disease severity (Coovert et al., 1997; Lefebvre et al., 1997) as confirmed in SMA mouse models (Frugier et al., 2000; Hsieh-Li et al., 2000; Monani et al., 2000) .
The ubiquitously expressed SMN protein is involved in the small nuclear ribonucleoprotein (snRNP) assembly machinery, which controls pre-mRNA splicing (Liu and Dreyfuss, 1996; Liu et al., 1997; Meister et al., 2001; Pellizzoni et al., 1998 Pellizzoni et al., , 2002 . SMN deficiency causes widespread splicing abnormalities in the SMA mouse model (Zhang et al., 2008) . In addition, SMN may exert some neuron-specific functions. Neurons with SMN deficiency have several defects, including decreased axon outgrowth (Rossoll et al., 2003; Ting et al., 2007) , impaired axon path-finding (McWhorter et al., 2003) , dysregulation of actin dynamics (Bowerman et al., 2007; Rossoll et al., 2003) , defects in presynaptic organization (Torres-Benito et al., 2011) , and disruption of microtubule networks (Wen et al., 2010) .
A microtubule destabilizing protein, stathmin/Op18, is a ubiquitous phosphoprotein that has a high expression during the development of the nervous system and becomes downregulated following terminal differentiation (Doye et al., 1989; Koppel et al., 1990; Peschanski et al., 1993) . The differential phosphorylation of stathmin controls microtubule dynamics (Larsson et al., 1997; Marklund et al., 1996) . We have previously shown that stathmin is dysregulated in SMA mice (Wen et al., 2010) . Knockdown of Stmn expression in SMA-like cells ameliorates defects in organelle transport and in the outgrowth of axons and microtubules (Wen et al., 2010) .
In this study, the role of stathmin in the progression of SMA was investigated by back-crossing SMA-like mice into Stmn knockout (KO) mice. Our results show that StmnKO did not prolong the lifespan of SMA-like mice. However, SMA-Stmn +/− mice had improved body weight gain, motor performance, and neuromuscular junction (NMJ) maturation. This improvement in neuromuscular pathology was likely due to a recovery of microtubules in axons, indicating a role for stathmin in the pathogenesis of motor axonal defects in SMA.
Materials and methods

Mice
SMA-like mice and Stmn −/− mice were generated as previously described (Hsieh-Li et al., 2000; Liedtke et al., 2002) . SMA-like mice with a StmnKO background were generated by a series of genetic crosses as described in Fig. 1 mice were initially maintained in the C57BL/6L strain; therefore, we backcrossed these mice to the FVB strain for six generations. Each allele was genotyped by using allele-specific primers (Hsieh-Li et al., 2000; Liedtke et al., 2002) .
Western blot analysis
Mouse tissues were homogenized or lysed in a RIPA buffer (150 mM NaCl, 50 mM Tris/HCl at pH 8.0, 2 mM EDTA, 0.5% sodium deoxycholate, 1% Nonidet P-40, 1 mM Na 3 VO 4 , 50 mM NaF) supplemented with a protease inhibitor cocktail (Merck, Darmstadt, Germany) . Equal amounts of boiled lysate were separated on SDSpolyacrylamide gels and then transferred to PVDF membranes. The membranes were incubated in a blocking solution (0.1 M PBS, 5% non-fat milk, 0.2% Tween-20) for 1 h at room temperature and then incubated in the same solution with the appropriate primary or secondary antibody. Finally, the membranes were visualized by using enhanced chemiluminescence (ECL; Perkin Elmer Life Sciences, Boston, MA). Relative densitometric values in western blots were analyzed by using AlphaEaseFC software (Alpha Innotech Corporation, San Leandro, CA).
Histological examination of spinal cord motor neurons
Lumbar spinal cords were fixed in 4% paraformaldehyde (PFA) and dehydrated in a series of sucrose solution. After serial sectioning at 60 μm intervals, the sections (10 μm each) were stained with Cresyl violet. Images were acquired by using a Zeiss Axio Image Z1 microscope (Carl Zeiss, Germany) with a 20 × objective. Motor neuron numbers were quantified by using Image-Pro Plus software (version 6, Media Cybernetics, Silver Springs, MD). 
Immunohistochemistry
Lumbar spinal cord cryosections (10 μm) were blocked and incubated with the glial fibrillary acid protein (GFAP) antibody (Merck Millipore), followed by incubation with Alexa Fluor 488 donkey anti-rabbit IgG (Molecular Probes, Invitrogen, Carlsbad, CA). Finally, samples were stained with DAPI (Sigma) for 5 min to identify nuclei and then mounted with a fluorescence mounting solution (Invitrogen). Confocal images were obtained by using a LSM710 microscope (Carl Zeiss) with a 20 × objective.
Assessment of motor performance
The Tube assay was measured as previously described (El-Khodor et al., 2008) . Briefly, mice were placed on a 50 mL plastic centrifuge tube by their hind-limbs and scores assigned based on the following criteria: score of 4, normal hind-limb separation with tail raised; score of 3, hind-limbs are closer together without touching each other; score of 2, hind-limbs are closer together and often touch each other; score of 1, hind-limbs are clasped with tail raised; and score of 0, hind-limbs are constantly clasped with the tail lowered.
Whole-mount staining
For whole-mount immunostaining, the gastrocnemius and tibialis anterior muscles were dissected out and fixed in 4% PFA for 2 h at 4°C. After extensive washing in 0.1 M PBS/0.1 M glycine 3 times, the muscles were blocked in a blocking buffer (3% BSA and 0.5% Triton-X100 in 0.1 M PBS), followed by incubation with antiNeurofilament H antibody (diluted to 1:1000; Merck Millipore) in a blocking solution overnight at 4°C. The following day, samples were washed in five changes of rinse solution (1% BSA, 0.5% Triton-X100 in 0.1 M PBS) over 5 h, and then incubated with Alexa Fluor 488 donkey anti-rabbit IgG and TRITC-conjugated α-bungarotoxin (α-BTX) (diluted to 1:1000; Molecular Probes, Invitrogen). After washing with five changes of rinse solution over a period of 5 h, muscle samples were mounted onto slides by using fluorescence mounting solution (Invitrogen). Confocal images were captured by using a LSM710 microscope (Carl Zeiss) with a 25 × objective. NMJ area measurements were made by using MetaMorph software (version 7.7, Molecular Devices, Downington, PA).
Electron microscopy
The sciatic nerves were fixed with 4% PFA and 2.5% glutaraldehyde in sodium cacodylate buffer. After extensive washing in sodium cacodylate buffer, the tissues were post-fixed in 1% osmium tetroxide in sodium cacodylate buffer. Following dehydration, the tissues were embedded in Spurr resin. Ultra-thin sections were stained with uranylacetate and lead citrate and then viewed by using a Tecnai G2Spirit Twin electron microscope (FEI Company, Hillsboro, OR). Microtubule densities were measured by using MetaMorph software (Molecular Devices).
Results
Generation of StmnKO SMA-like mice
A previous study has shown that the aberrant expression of Stmn in SMA-like mice correlates with SMA disease severity (Wen et al., 2010) . To further investigate whether a decrease in stathmin levels prevents the development of SMA pathology, a series of genetic crosses of mice was conducted to generate SMA-like mice with a StmnKO background ( ). This result shows that the stathmin protein levels in each group corresponded to their genotypes (Fig. 1B) .
Heterozygous StmnKO but not homozygous StmnKO increases microtubule density in SMA-like mice SMA-like mice were previously shown to have about 26% fewer microtubules per axon than normal mice (Wen et al., 2010) . We therefore asked whether depletion of stathmin levels could influence microtubule density in SMA-like mice. Sciatic axons were isolated from SMA-like mice of each genotype and their littermate controls and determined the number of microtubules by electron microscopy. There was no significant change in microtubule density in the control group (Figs , led to the improvement in the microtubule defect that was identified in SMA-like mice (Wen et al., 2010) .
StmnKO fails to prolong the lifespan of SMA-like mice
In an attempt to address whether down-regulation of stathmin could be beneficial for SMA-like mice, a series of cross-mating experiments was conducted. Analysis of a total of 181 SMA-like mice born from 61 litters showed that StmnKO did not confer a survival advantage over SMA-like mice (Fig. 3A) . The maximal survival time (MST) of the SMA-Stmn +/+ and SMA-Stmn −/− mice was 14 and 16 days, with an average and median survival time of 9 and 10 days, respectively. One mouse in the SMA-Stmn +/− group showed an unexpected MST of 41 days, but this group still had an average and median survival time of 10 days. Additionally, the body weight of mice of each genotype was measured every morning. Regardless of genotype, all mice initially exhibited similar body weights (Fig. 3B) . From PND 4 to 14, control littermates had continually increasing body weights; however, the body weight gain in SMA-like mice was impaired. Interestingly, the pups in the StmnKO groups (SMA-Stmn +/− and SMA-Stmn −/− ) had increased body weight compared to SMA-Stmn +/+ mice from PND 9 to 14, and SMA-Stmn +/− mice differed significantly in body weight compared to SMA-Stmn +/+ mice ( Fig. 3B , P b 0.05). In contrast, there was no statistical difference in body weight gain between the three control group genotypes ( Fig. 3B , P = 0.944). These data indicate that StmnKO improves body weight gain in SMA-like mice.
Heterozygous StmnKO improves motor activity in SMA-like mice
Although StmnKO does not fully rescue the SMA-like phenotype, the body weight gain of SMA-like mice with a StmnKO background was enhanced, indicating an improvement in their energy intake. We then assessed the motor activity in each mouse genotype by Tube assay through PND 3. The motor performance was scored from 4 to 0 based on the hind-limb strength (see details in Materials and methods section). As expected, the control groups had excellent motor performance (Fig. 4) (Fig. 4) . However, SMA-Stmn +/− mice showed deterioration in motor performance starting at PND13. This result indicates that Stmn +/− delayed the decline in motor function of SMA-like mice.
Decrease in stathmin levels does not prevent motor neuron death in SMA-like mice
Since an improvement in the motor performance of Stmn +/− mice was observed, we asked whether this could be caused by the prevention of motor neuron death due to decreased stathmin levels. Motor neuron counts were then measured in spinal cord sections from each genotype of SMA-like and control mice at PND 9 and 12 by Nissl staining. The results showed no significant change in motor neuron numbers between the three genotypes of control mice at PND 9 (control-Stmn +/+ , 12.04 ± 0.31 vs. control-Stmn (Figs. 5A-D) . SMA-like mice had fewer motor neurons than did control littermates at PND 9 and PND 12 (Figs. 5A-D In addition, the amount of SMN protein expressed directly correlated with SMA severity. We analyzed SMN protein levels in the spinal cords of mice of each SMA-like genotype and control littermates at PND 9 and PND 12 by Western blot. Decreased levels of SMN protein expression were observed in SMA-like mice compared to control littermates (Figs. 5E and F), and no significant differences were seen between mice in the SMA-Stmn 
Heterozygous StmnKO ameliorates neuromuscular junction (NMJ) defects in SMA-like mice
To examine whether the observed improvement in motor performance could be attributed to the modification of NMJ defects by decreased stathmin levels, the structure and size of the NMJ in the tibialis anterior muscle and gastrocnemius muscle in each genotype of SMA-like mice and control littermates were evaluated at PND 9 and 12. The NMJ maturation process involves a transition in acetylcholine receptor (AChR) cluster shape from plaque to pretzel morphology and an increase in size. This process was previously shown to be defective under SMA (Riessland et al., 2010) . Postsynaptic AChRs were visualized by using α-BTX staining of the muscle. The AChRs were classified into four morphology types: (1) Uniform: NMJs are immature and appear as oval plaques with even distribution of AChRs; (2) Folds: Plaques have bright bands and form post-synaptic folds; (3) Perforated: Plaques have single or multiple small holes; (4) Pretzel-like: Plaques have a pretzellike shape (Fig. 6A) (Bolliger et al., 2010; Marques et al., 2000) . Here, we combined all genotypes of control mice as the control group because there was no significant difference in their body weight, motor performance, or motor neuron counts. The results showed that over 50% of the NMJs were immature, showing uniform plaques in the tibialis anterior muscle of the SMA-like group (SMA-Stmn +/+ , 58.33% ± 2.47%; SMA-Stmn +/− , 52.75% ± 1.27%;
and SMA-Stmn −/− , 60.55% ± 1.62%) and in the gastrocnemius muscle (SMA-Stmn +/+ , 58.72% ± 2.53%; SMA-Stmn +/− , 53.43% ± 1.65%;
and SMA-Stmn −/− , 65.31% ± 0.94%) at PND 9 (Figs. 6, B and C). In contrast, the control group showed a lower percentage of immature NMJs in both the tibialis anterior muscle (11.46% ± 1.3%) and the gastrocnemius muscle (16.46% ± 1.12%) (Figs. 6, B and C). As expected, the percentage of immature NMJs decreased at PND 12 in both SMA-like mice and control mice (Figs. 6, D and E) . Interestingly, the SMA-Stmn +/− group had a significantly lower percentage of plaques with a uniform structure and a higher percentage with pretzel-like structure compared to the SMA-Stmn +/+ and SMAStmn −/− groups in both the tibialis anterior muscle (Uniform:
7.16% ± 1% vs.18.67% ± 1.68%, P = 0.0009; 7.16% ± 1% vs. 16.76% ± 1.16%, P = 0.0016; Pretzel-like: 9.15% ± 0.69% vs. 2.26% ± 0.42%, P b 0.0001, and 9.15% ± 0.69% vs. 2.64% ± 0.14%, P = 0.0005) and in the gastrocnemius muscle (Uniform: 10.43% ± 3.44% vs. 31.6% ± 2.85%, P = 0.003, and 10.43% ± 3.44% vs. 26.6% ± 2.77%, P = 0.0217; Pretzel-like: 10.55% ± 2.2% vs. 0.5% ± 0.48%, P = 0.0012, and 10.55% ± 2.2% vs. 0.79% ± 0.79%, P = 0.0148) at PND 12 (Figs. 6, D and E) . In addition, the NMJs were significantly larger in both the tibialis anterior and the gastrocnemius muscles in the SMA-Stmn +/− group compared to the SMA-Stmn +/+ and SMA-Stmn −/− groups at PND 12 (Figs. 6, F and G). Taken together, these results indicate that Stmn +/− ameliorates defects in NMJ maturation in SMA-like mice.
Heterozygous StmnKO reduced neuroinflammation in SMA-like mice
Neuroinflammation is a cellular process induced by microglial and astroglial activations and participates in the progression of neuronal degeneration (Papadimitriou et al., 2010) . Stathmin has been identified as an agonist for Toll-like receptor 3 (TLR3)-dependent signaling in astrocyte and microglia, suggesting a potential link between stathmin and neuroinflammation (Bsibsi et al., 2010) . We therefore investigated whether stathmin dysregulation under SMA possibly induces neuroinflammation and contributes to the pathogenesis of SMA. Lumbar spinal cord sections from SMA-like and control groups at PND 9 and 12 were stained for GFAP which is the typical method of examination of gliosis indicative of neuroinflammation (Fig. 7) . The result showed that gliosis developed in SMA-Stmn
, and SMA-Stmn −/− groups, but were rarely observed in control groups at PND 9 at PND 12 (Figs. 7A and B) , supporting possible involvement of neuroinflammation in SMA pathogenesis. Interestingly, the SMA-Stmn +/− group revealed milder gliosis than the SMA-Stmn
and SMA-Stmn −/− groups, suggesting that stathmin may be involved in neuroinflammation under SMA conditions.
Discussion
We have previously shown that stathmin levels correlate with the disease severity in SMA-like mice (Wen et al., 2010) . Herein, we show that reduction (Stmn and 6). These data together suggest that stathmin may play a role in the axonal pathogenesis of SMA but is not associated with the death of SMA-like mice. A previous report showed that motor neuron rescue in an inducible severe SMA mouse model improved motor activity but led to only minimal improvement in survival (Gogliotti et al., 2012) . Cardiac dysfunction, which has been described in an SMA mouse model (Bevan et al., 2010; Heier et al., 2010) and in several clinical studies (Hachiya et al., 2005; Rudnik-Schoneborn et al., 2008; Tanaka et al., 1977) , still occurred in motor neuron-rescued SMA mice (Gogliotti et al., 2012) . SMA cardiac defects are believed to be involved in respiratory distress and death. Together, our results showed that Stmn +/− and Stmn −/− do not prevent death in SMA-like mice, which may be caused by cardiac deficiencies related to SMA. Insulin-like growth factor (IGF-1) is a neuroprotective trophic factor that has been shown to improve disease phenotypes in mouse models of amyotrophic lateral sclerosis (ALS) (Kaspar et al., 2003) and spinal and bulbar muscular atrophy (SBMA) (Palazzolo et al., 2009) . A previous study showed that IGF-1 and IGF-binding protein, and acid labile subunit (IGFALS) are downregulated in an SMA mouse model (Hua et al., 2011) . Transgenic IGF-1 expression in muscle resulted in an increase in muscle size, body weight, and lifespan in an SMA mouse model (Bosch-Marce et al., 2011) , suggesting that IGF-1 protein could be a potential factor for use in SMA therapy. Notably, IGF-1 expression is increased in embryonic fibroblasts derived from Stmn −/− mice (Ringhoff and Cassimeris, 2009) , suggesting that decreased stathmin levels may lead to improvements in SMA pathology by increasing IGF-1 protein levels. Cytoskeletal defects, such as dysregulation of actin dynamics (Bowerman et al., 2007 (Bowerman et al., , 2010 McWhorter et al., 2003; Nolle et al., 2011) , neurofilament accumulation (Cifuentes-Diaz et al., 2002), and microtubule disturbance (Torres-Benito et al., 2011; Wen et al., 2010) , have been observed in SMA animals and were found to correlate with SMA pathology. In our previous work, we showed that Stmn-knockdown ameliorated defects in microtubule regrowth and axon outgrowth in Smn-knockdown cells and microtubulebased mitochondrial transport in SMA-like motor neuron cultures (Wen et al., 2010) . Here, we show that SMA-Stmn +/− mice had a higher microtubule density and more mature NMJs than did SMA-Stmn +/+ or SMA-Stmn −/− mice (Figs. 2 and 6 ), indicating that downregulation of aberrant stathmin levels (Fig. 1D , SMAStmn +/+ vs. control-Stmn +/+ ) partly diminished the defects in SMA-like mice. Interestingly, SMA-Stmn −/− mice had worse motor performance (Fig. 4) , shorter mean lifespan (Fig. 3A) , and fewer beneficial effects over SMA-like mice than did SMA-Stmn +/− mice. Gene expression profiles have revealed that the expression of tubulin isotypes is altered in Stmn −/− mouse embryonic fibroblasts (Ringhoff and Cassimeris, 2009) . Protein levels of a predominant neuronal tubulin, the β-III isoform, were decreased in Stmn −/− cells (Ringhoff and Cassimeris, 2009 ). In contrast, Stmn +/− cells showed a protein level pattern similar to that of Stmn +/+ cells (Ringhoff and Cassimeris, 2009) . A lack of developmental defects in the nervous system of Stmn −/− mice was reported, but those mice still revealed some axonal changes, and an axonopathy was found in aging mice (Liedtke et al., 2002) . These findings indicate that stathmin plays a role in the maintenance of the tubulin pool; therefore, complete absence of stathmin has negative effects on the regulation of the microtubule network. Tissue-specific depletion or rescue of SMN expression using the Cre-loxP system in the SMA-like mouse model has been used to demonstrate that motor neuron pathology in SMA is the cell-autonomous effect of SMN insufficiency and provided evidence that defects in non-neuronal tissue correlate with disease severity (Gogliotti et al., 2012; Park et al., 2010) . Clinical studies also reported that gliosis occurred in the spinal cords and brain stems of SMA patients (Araki et al., 2003; Garcia-Cabezas et al., 2004; Kuru et al., 2009 ). These findings provide evidence that non-cell autonomous effects may possibly contribute to SMA pathogenesis. Increased stathmin levels reported in the brains of multiple sclerosis (MS) patients were identified in the microglia, astrocytes, and oligodendrocytes of damaged tissue during inflammation (Bsibsi et al., 2010; Chabas et al., 2001; Liu et al., 2005) . In addition, stathmin has been identified as an agonist for TLR3-dependent signaling in astrocytes and microglia and mediates pro-and anti-inflammatory response cytokine secretion (Bsibsi et al., 2010) . Human microglia cells stimulated with stathmin significantly induce IL-13 (Bsibsi et al., 2010) , which has been shown to induce oxidative stress through NAPDH oxidase and cause the degeneration of hippocampal neurons (Park et al., 2009) . Two of the cytokines, TNF-α and IL-1β, that are activated in microglia by stathmin stimulation (Bsibsi et al., 2010) have been reported to cause neurodegeneration (De Lella Ezcurra et al., 2010; Zhao et al., 2009 ). Together, these findings support that neuroinflammation and oxidative stress could be induced upon abnormal stathmin activation during SMA.
In conclusion, our data indicate that downregulation of aberrantly expressed stathmin in SMA-like mice improves NMJ maturation in the tibialis anterior and the gastrocnemius muscles. This improvement may be due to increased microtubule density in axons, which contributes to the amelioration of some of the defects associated with SMA.
